Minnetronix Neuro Successfully Completes First Clinical Study in Hemorrhagic Stroke
Minnesota-based Company to Present at Late Breaking Session during Congress of Neurological Surgeons
Contract med-tech manufacturer Minnetronix to launch own device
Minnetronix is developing a product that removes contaminants in the cerebral spinal fluid after a hemorrhagic stroke.
Feasibility of Neurapheresis™ Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis
October 4, 2017 - Duke University Medical Center/Minnetronix Neuro Pseudomonas, Acinetobacter and Klebsiella are three multidrug resistant (MDR) gram-negative pathogens that pose a threat to human health. Patients in hospitals…